|
| ||||||||||||||
Laquinimod Demonstrated Significant and Sustained Impact on Multiple Sclerosis Disease Activity LUND, SWEDEN--(MARKET WIRE)--Sep 18, 2008 -- New Crossover Data Presented at the World
Congress on Treatment and
Research in Multiple Sclerosis Shows Significant Reduction
of
Gadolinium-Enhancing Lesions - Jerusalem, Israel and Lund, Sweden, September 18, 2008 - New data from the extension phase of oral laquinimod in relapsing-remitting multiple sclerosis (RRMS) demonstrated a significant reduction in the mean number of gadolinium-enhancing (GdE) lesions in both patients who switched from placebo to laquinimod and patients who continued with their initial laquinimod dose. In RRMS patients who switched from placebo to laquinimod, 52 percent reduction in the mean number of GdE lesions was observed (p < 0.0007). The reduction was significant for both patients switching to high-dose (p < 0.009) and low-dose laquinimod (p < 0.03). In addition, the proportion of patients who switched to active treatment from placebo, and remained enhancing lesion-free, increased from 31 percent to 47 percent (p < 0.012), further reinforcing the efficacy of laquinimod on magnetic resonance imaging (MRI) measured disease activity. Active Biotech is required under the Financial Instruments Trading Act to make the information in this press release public. The information was submitted for publication at 9:30 p.m. CET on September 18, 2008. Attachments: http://hugin.info/1002/R/1252709/272574.pdf Copyright © Hugin AS 2008. All rights reserved. Contact: Contact:
Elana Holzman
Teva Pharmaceutical Industries Ltd.
972 (3) 926-7554
Kevin Mannix
Teva North America
(215) 591-8912
Source: Active Biotech
|  | |||||||||||||
